India’s Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
Topstory
US Proposal Could Halve Biocon’s Biosimilar Development Costs
by aweeincm1
Recent Post
Congress Has Become More Leftist To Counter BJP: Shashi Tharoor
Congress MP Shashi Tharoor on Thursday said the party has ... Read more
Delhi Blast Probe Trail Leads To Dubai, Where Suspect Went Via Pakistan: Sources
The investigation into the Delhi car bomb blast that killed ... Read more
Jeff Bezos’s Blue Origin Launches NASA’s ESCAPADE Mission To Mars
The Blue Origin space venture of Jeff Bezos launched its ... Read more
BBC Apologises To Trump Over Speech Edit, Rejects Compensation Claim
Britain’s BBC apologised to Donald Trump on Thursday for editing ... Read more